Trial Outcomes & Findings for Kaiser Permanente HIV Cohort Study (NCT NCT01339403)

NCT ID: NCT01339403

Last Updated: 2015-04-03

Results Overview

Incidence rate of malignancies was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were Kaiser Permanente (KP) member from the date of HIV care initiation at that institution or January 1, 1996 for KP Northern California(KPNC) and January 1, 2000 for KP Southern California(KPSC) if in care prior to this date. Malignancies included acquired immunodeficiency syndrome (AIDS)-defining malignancies and non-AIDS defining malignancies.AIDS-defining malignancies included invasive cervical cancer,invasive non-Hodgkin's lymphoma and kaposi's sarcoma;non-AIDS defining malignancies cancers ascertained from the KP cancer registries.Overall data for non-AIDS and AIDS defining malignancies, along with individual data for AIDS-defining malignancies was reported. Incidence rate was computed as the number of events per 100,000 person-years.

Recruitment status

COMPLETED

Target enrollment

282368 participants

Primary outcome timeframe

Up to Week 835

Results posted on

2015-04-03

Participant Flow

Participants infected and uninfected with Human Immunodeficiency Virus (HIV) were recruited and analyzed retrospectively in the Kaiser Permanente HIV registry.

Participant milestones

Participant milestones
Measure
Cohort 1: HIV Infected
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Overall Study
STARTED
24768
257600
Overall Study
COMPLETED
24768
257600
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Kaiser Permanente HIV Cohort Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Total
n=282368 Participants
Total of all reporting groups
Age, Customized
Less than (<) 35 years
6883 participants
n=99 Participants
76826 participants
n=107 Participants
83709 participants
n=206 Participants
Age, Customized
Between 35 and 39 years
4919 participants
n=99 Participants
50657 participants
n=107 Participants
55576 participants
n=206 Participants
Age, Customized
Between 40 and 44 years
4700 participants
n=99 Participants
47564 participants
n=107 Participants
52264 participants
n=206 Participants
Age, Customized
Between 45 and 49 years
3701 participants
n=99 Participants
37184 participants
n=107 Participants
40885 participants
n=206 Participants
Age, Customized
Between 50 and 54 years
2302 participants
n=99 Participants
22942 participants
n=107 Participants
25244 participants
n=206 Participants
Age, Customized
Between 55 and 59 years
1246 participants
n=99 Participants
12199 participants
n=107 Participants
13445 participants
n=206 Participants
Age, Customized
Between 60 and 64 years
613 participants
n=99 Participants
6154 participants
n=107 Participants
6767 participants
n=206 Participants
Age, Customized
Greater than (>) 65 years
404 participants
n=99 Participants
4074 participants
n=107 Participants
4478 participants
n=206 Participants
Sex: Female, Male
Female
2306 Participants
n=99 Participants
24134 Participants
n=107 Participants
26440 Participants
n=206 Participants
Sex: Female, Male
Male
22462 Participants
n=99 Participants
233466 Participants
n=107 Participants
255928 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of malignancies was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were Kaiser Permanente (KP) member from the date of HIV care initiation at that institution or January 1, 1996 for KP Northern California(KPNC) and January 1, 2000 for KP Southern California(KPSC) if in care prior to this date. Malignancies included acquired immunodeficiency syndrome (AIDS)-defining malignancies and non-AIDS defining malignancies.AIDS-defining malignancies included invasive cervical cancer,invasive non-Hodgkin's lymphoma and kaposi's sarcoma;non-AIDS defining malignancies cancers ascertained from the KP cancer registries.Overall data for non-AIDS and AIDS defining malignancies, along with individual data for AIDS-defining malignancies was reported. Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Malignancies
Kaposi's sarcoma
513 malignancies per 100,000 person-years
3 malignancies per 100,000 person-years
Incidence Rate of Malignancies
Invasive non-Hodgkin's lymphoma
238 malignancies per 100,000 person-years
20 malignancies per 100,000 person-years
Incidence Rate of Malignancies
Invasive cervical cancer
25 malignancies per 100,000 person-years
7 malignancies per 100,000 person-years
Incidence Rate of Malignancies
Non-AIDS-defining cancer
633 malignancies per 100,000 person-years
384 malignancies per 100,000 person-years
Incidence Rate of Malignancies
AIDS-defining cancer
740 malignancies per 100,000 person-years
23 malignancies per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of cardiovascular (CVS)events including myocardial infarction (MI) and ischemia was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Myocardial Infarction and Ischemia
435 CVS events per 100,000 person-years
313 CVS events per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of AIDS-defining opportunistic infections (OI) was calculated as the number of events divided by person-time.Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1,1996 for KPNC and January 1,2000 for KPSC if in care prior to this date.OI were those that occurred on immune-compromised participants.AIDS-defining infections included:wasting syndrome;pneumocystis jirovecii pneumonia;recurrent pneumonia;cytomegalovirus;HIV-related encephalopathy;esophageal candidiasis;mycobacterium avium complex;cryptococcosis;mycobacterium tuberculosis;progressive multifocal leukoencephalopathy;lung candidiasis;toxoplasmosis of brain;coccidiomycosis;histoplasmosis;recurrent salmonella septicemia;chronic isosporiasis;cryptosporidiosis.Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Wasting syndrome
1002 infections per 100,000 person-years
15 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Pneumocystis jirovecii pneumonia
760 infections per 100,000 person-years
2 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Recurrent pneumonia
640 infections per 100,000 person-years
74 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Cytomegalovirus
440 infections per 100,000 person-years
5 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
HIV-related Encephalopathy
405 infections per 100,000 person-years
NA infections per 100,000 person-years
No participant in this arm was evaluated for HIV-related encephalopathy, since only HIV infected participants were assessed for this infection.
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Esophageal Candidiasis
383 infections per 100,000 person-years
6 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Mycobacterium avium complex
259 infections per 100,000 person-years
3 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Cryptococcosis
187 infections per 100,000 person-years
1 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Mycobacterium tuberculosis
157 infections per 100,000 person-years
25 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Progressive multifocal leukoencephalopathy
78 infections per 100,000 person-years
0 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Lung Candidiasis
63 infections per 100,000 person-years
6 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Toxoplasmosis of brain
58 infections per 100,000 person-years
1 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Coccidiomycosis
9 infections per 100,000 person-years
1 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Histoplasmosis
20 infections per 100,000 person-years
2 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Recurrent Salmonella septicemia
2 infections per 100,000 person-years
0 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Chronic Isosporiasis
0 infections per 100,000 person-years
0 infections per 100,000 person-years
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Cryptosporidiosis
72 infections per 100,000 person-years
0 infections per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of liver failure was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Liver Failure
492 liver failure per 100,000 person-years
105 liver failure per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of liver related death was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Liver Related Death
202 death per 100,000 person-years
29 death per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of Rhabdomyolysis was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Rhabdomyolysis
235 rhabdomyolysis per 100,000 person-years
28 rhabdomyolysis per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 835

Population: Analysis population included all participants enrolled in the study.

Incidence rate of all-cause mortality was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of All-Cause Mortality
1827 death per 100,000 person-years
326 death per 100,000 person-years

PRIMARY outcome

Timeframe: Up to Week 730

Population: Analysis population included all participants enrolled in the study.

Incidence rate of viral encephalitis (VE) was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years. The participants with viral encephalitis were followed-up up to 31st December 2009 (730 Weeks).

Outcome measures

Outcome measures
Measure
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
Incidence Rate of Viral Encephalitis
30 VE per 100,000 person-years
2 VE per 100,000 person-years

Adverse Events

Cohort 1: HIV Infected

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Cohort 2: HIV Uninfected

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Results disclosure agreements

  • Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
  • Publication restrictions are in place

Restriction type: OTHER